Selected studies of frontline treatment in older patients with DLBCL in the rituximab era
| Reference . | Treatment . | Age, median (range), y . | No. of patients . | PFS, % . | OS, % . |
|---|---|---|---|---|---|
| Delarue et al28 | 8 R-CHOP14 | 70 (60-80) | 304 | 60 (3 y) | 69 (3 y) |
| 8 R-CHOP21 | 70 (59-80) | 298 | 62 (3 y) | 72 (3 y) | |
| Peyrade et al6 | 6 R-miniCHOP | 83 (80-95) | 149 | 47 (2 y) | 59 (2 y) |
| Peyrade et al29 | 6 Ofatumumab-miniCHOP | 83 (80-95) | 120 | 57 (2 y) | 65 (2 y) |
| Merli et al23 | 6 Obinutuzumab-miniCHOP | 82 (68-89) | 34 | 49 (2 y) | 68 (2 y) |
| Oberic et al30 | 6 R-miniCHOP vs 6 R-miniCHOP + lenalidomide | 83 (80-96) | 127 | 56 (2 y) | 66 (2 y) |
| 122 | 55 (2 y) | 66 (2 y) | |||
| Moccia et al31 | 6-8 R-CEOP21 | 73 (34-93) | 70 | 53 (5 y) | 47 (5 y) |
| 6-8 R-CHOP21 | 73 (21-92) | 140 | 69 (5 y) | 65 (5 y) | |
| Shen et al32 | 6 R-GemOx | 60-69 | 14 | 71 (3 y) | 78 (3 y) |
| ≥70 | 46 | 42 (3 y) | 61 (3 y) | ||
| Fields et al33 | 6 R-GCVP | 76 (52-90) | 27 (LVEF ≤50%) | 55 (2 y) | 66 (2 y) |
| 35 (LVEF >50%) | 45 (2 y) | 46 (2 y) | |||
| Storti et al34 | 4-6 R-Benda + 2 R | 81 (71-89) | 45 | 38 (2 y) | 51 (2 y) |
| Reference . | Treatment . | Age, median (range), y . | No. of patients . | PFS, % . | OS, % . |
|---|---|---|---|---|---|
| Delarue et al28 | 8 R-CHOP14 | 70 (60-80) | 304 | 60 (3 y) | 69 (3 y) |
| 8 R-CHOP21 | 70 (59-80) | 298 | 62 (3 y) | 72 (3 y) | |
| Peyrade et al6 | 6 R-miniCHOP | 83 (80-95) | 149 | 47 (2 y) | 59 (2 y) |
| Peyrade et al29 | 6 Ofatumumab-miniCHOP | 83 (80-95) | 120 | 57 (2 y) | 65 (2 y) |
| Merli et al23 | 6 Obinutuzumab-miniCHOP | 82 (68-89) | 34 | 49 (2 y) | 68 (2 y) |
| Oberic et al30 | 6 R-miniCHOP vs 6 R-miniCHOP + lenalidomide | 83 (80-96) | 127 | 56 (2 y) | 66 (2 y) |
| 122 | 55 (2 y) | 66 (2 y) | |||
| Moccia et al31 | 6-8 R-CEOP21 | 73 (34-93) | 70 | 53 (5 y) | 47 (5 y) |
| 6-8 R-CHOP21 | 73 (21-92) | 140 | 69 (5 y) | 65 (5 y) | |
| Shen et al32 | 6 R-GemOx | 60-69 | 14 | 71 (3 y) | 78 (3 y) |
| ≥70 | 46 | 42 (3 y) | 61 (3 y) | ||
| Fields et al33 | 6 R-GCVP | 76 (52-90) | 27 (LVEF ≤50%) | 55 (2 y) | 66 (2 y) |
| 35 (LVEF >50%) | 45 (2 y) | 46 (2 y) | |||
| Storti et al34 | 4-6 R-Benda + 2 R | 81 (71-89) | 45 | 38 (2 y) | 51 (2 y) |
PFS, progression-free survival; R-CEOP, rituximab, cyclophosphamide, etoposide, vincristine and prednisone; R-Benda, rituximab and bendamustine; R, rituximab; R-GCVP, rituximab, gemcitabine, cyclophosphamide, vincristine and prednisone; R-GemOx, rituximab, gemcitabine and oxaliplatin.